Skip to main content
Premium Trial:

Request an Annual Quote

Anne-Fabienne Weitsch, Laura Francis, Eric Lachenmeier

Premium

Hybrigenics has appointed Anne-Fabienne Weitsch to the position of chief operating officer, the Paris-based functional proteomics company said last week. Weitsch, who most recently served at Johnson & Johnson as senior director of licensing and business development, will be responsible for all aspects of Hybrigenics’ management, business development and drug discovery activities, the company said. Prior to Johnson & Johnson, Weitsch worked at the Janssen Research Foundation as senior director, collaborations and technology transfer, and at Zyma, a CIBA company, in a number of R&D positions.

 

Laura Francis has joined Bruker AXS as chief financial officer, the Madison, Wis.-based company said. Most recently, Francis served as CFO of start-up companies Hypercosm and Nutra-Park. Previously, she served as an engagement manager at McKinsey & Co. In addition to her duties as CFO, Francis will also be responsible for investor relations.

 

Aviva Biosciences has appointed Eric Lachenmeier director of business development, the San Diego-based biochip company said. In previous positions, Lachenmeier served as vice president for technology development at Incyte Genomics, and as an R&D project director and engineer at Lynx Therapeutics and Applied Biosystems.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.